Patents by Inventor Lara S. Kallander

Lara S. Kallander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazoline compounds
    Patent number: 8859571
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: October 14, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Lara S. Kallander, Brian Griffin Lawhorn, Joanne Philp
  • COMPOUNDS AND METHODS
    Publication number: 20120329784
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, and R6 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: January 11, 2011
    Publication date: December 27, 2012
    Inventors: Lara S. Kallander, Brian Griffin Lawhorn, Joanne Philp, Yongdong Zhao
  • QUINAZOLINE COMPOUNDS
    Publication number: 20120220588
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: November 1, 2010
    Publication date: August 30, 2012
    Inventors: Lara S. Kallander, Brian Griffin Lawhorn, Joanne Philp
  • Process for the preparation of renin inhibitors
    Patent number: 8242290
    Abstract: Disclosed is a process for the preparation of a tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: August 14, 2012
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: Paul G. Spoors, Lara S. Kallander, David A. Claremon
  • COMPOUNDS AND METHODS
    Publication number: 20120157482
    Abstract: Disclosed are compounds having the formula: wherein R1 and R2 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: August 25, 2010
    Publication date: June 21, 2012
    Inventors: Alan Peterson Graves, III, Lara S. Kallander, Patrick Stoy
  • Renin Inhibitors
    Publication number: 20100317697
    Abstract: Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: June 20, 2008
    Publication date: December 16, 2010
    Inventors: John J. Baldwin, Salvacion Cacatian, David Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Bahman Ghavimi-Alagha, Damiano Ghirlanda, Alexey V. Ishchenko, Lara S. Kallander, Brian Lawhorn, Qing Lu, Gerard McGeehan, Beth A. Knapp-Reid, Simon Semus, Robert D. Simpson, Suresh B. Singh, Lamont R. Terrell, Colin Tice, Tritin Tran, Zherong Xu, Jing Yuan, Wei Zhao, Yongdong Y. Zhao
  • PROCESS FOR THE PREPARATION OF RENIN INHIBITORS
    Publication number: 20100256400
    Abstract: Disclosed is a process for the preparation of a tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.
    Type: Application
    Filed: September 17, 2008
    Publication date: October 7, 2010
    Inventors: Paul G. Spoors, Lara S. Kallander, David A. Claremon
  • RENIN INHIBITORS
    Publication number: 20100179109
    Abstract: Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: April 4, 2008
    Publication date: July 15, 2010
    Inventors: Jonh J. Baldwin, Salvacion Cacatian, David Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Bahman Ghavimi-Alagha, Damiano Ghirlanda, Alexey V. Ishchenko, Lara S. Kallander, Brian Lawhorn, Colin A. Leach, Qing Lu, Gerard McGeehan, Jaclyn R. Patterson, Robert D. Simpson, Suresh B. Singh, Patrick Stoy, Lamont R. Terrell, Colin Tice, Zhenrong Xu, Jing Yuan, Catherine C. K. Yuan, Jing Zhang, Wei Zhao
  • Renin Inhibitors
    Publication number: 20100130471
    Abstract: Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: April 4, 2008
    Publication date: May 27, 2010
    Inventors: John J. Baldwin, Salvacion Cacatian, David Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Bahman Ghavimi-Alagha, Damiamo Ghirlanda, Xiaoping Hou, Alexey V. Ishebenko, Lara S. Kallander, Beth A. Knapp-Reed, Brian Lawhorn, Qing Lu, Gerard McGeehan, Simon Semus, Robert D. Simpson, Suresh B. Singh, Lamont R. Terrell, Colin Tice, Tritin Tran, Zhenrong Xu, Jing Yuan, Jing Zhang, Wei Zhao
  • RENIN INHIBITORS
    Publication number: 20090275581
    Abstract: Disclosed are compounds according to Formula I: wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.
    Type: Application
    Filed: April 5, 2007
    Publication date: November 5, 2009
    Inventors: John J. Baldwin, David A. Claremon, Colin M. Tice, Salvacion Cacatian, Lawrence W. Dillard, Alexey V. Ishchenko, Jing Yuan, Zhenrong Xu, Gerard McGeehan, Wei Zhao, Robert D. Simpson, Suresh B. Singh, Patrick T. Flaherty, Lara S. Kallander, Colin A. Leach, Brian Lawhorn, Qing Lu, Lamont R. Terrell, Bahman Ghavini-Alagha, Jing Zhang, Damiano Ghirlanda, Xiaoping Hou, Simon Semus
  • Acid and ester compounds and methods of using the same
    Patent number: 7560586
    Abstract: Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: July 14, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Scott K. Thompson, Lara S. Kallander, Chun Ma, Joseph Marino, Dennis Lee
  • Cyanoarylamines
    Publication number: 20080194536
    Abstract: The present invention relates to a compound represented by the following formula: (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or a combination thereof, wherein Ro, R1, R1?, R2, R2?, R3 and n are defined herein. The present invention further relates to a method of treating a patient from endometreosis or uterine fibroids.
    Type: Application
    Filed: April 14, 2006
    Publication date: August 14, 2008
    Inventors: Marlys Hammond, David G. Jones, Istvan Kaldor, Lara S. Kallander, Xi Lang, Scott Kevin Thompson, Philip Stewart Turnbull, David G. Washburn
  • Compounds and methods
    Patent number: 7365085
    Abstract: Disclosed is a compound having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: April 29, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Ajita Bhat, John Jeffrey McAtee, Scott K. Thompson, James S. Frazee, Lara S. Kallander, Chun Ma, Joseph Marino, Michael J. Neeb, Robert A. Stavenger
  • Compounds and methods
    Patent number: 7323494
    Abstract: Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: January 29, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Scott K. Thompson, James S. Frazee, Lara S. Kallander, Chun Ma, Joseph Marino, Michael J. Neeb, Ajita Bhat
  • Amide compounds and methods of using the same
    Patent number: 7247748
    Abstract: Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: July 24, 2007
    Assignee: SmithKline Corporation
    Inventors: Scott K. Thompson, James S. Frazee, Lara S. Kallander, Chun Ma, Joseph P. Marino, Michael J. Neeb, Ning Wang
  • Compounds and methods
    Publication number: 20040192914
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: April 9, 2004
    Publication date: September 30, 2004
    Inventors: Lara S Kallander, M Dominic Ryan, Scott K Thompson
  • Compounds and methods
    Publication number: 20030220371
    Abstract: Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinophathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
    Type: Application
    Filed: October 10, 2002
    Publication date: November 27, 2003
    Inventors: Lara S. Kallander, Scott Thompson